Background: Calcitonin gene–related peptide (CGRP) receptor antagonist (collectively known as gepant) have emerged as effective therapies for both acute migraine treatment and preventive management.

Rimegepant is an orally disintegrating tablet (ODT) - a class of medications called calcitonin gene-related peptide (CGRP) receptor antagonist Approved by DCGI for acute treatment of migraine with or ...

Migraine is a growing public health concern in India. According to a study published in The Journal of Headache and Pain, nearly 26.3% of people in Delhi NCR suffer from the condition. Pfizer on ...

Drug maker Pfizer on Monday said it has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan ...

Global pharmaceutical company Pfizer has announced the launch of a Rimegepant Orally Disintegrating Tablet (ODT) in India for acute treatment of migraine in adults with a previous insufficient ...

ED Cracks Down on Punjab Drug Cartel: Key Middleman Abhishek Kumar Arrested in Rs 3.75 Crore Money Laundering Probe (11-12-2025) ...

Drug maker Pfizer on Monday said it has launched a new medication, Rimegepant ODT, in India for migraine treatment in adults with a previous insufficient response to triptan, the usual drug used for ...

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...

Pfizer launches new migraine drug in India (Image Source: Freepik) Drug maker Pfizer on Monday introduced a new migraine treatment in India, offering hope to millions who struggle with severe and ...

Pfizer has launched Rimegepant ODT, a new migraine treatment in India. It offers rapid, lasting relief and targets patients who do not respond to conventional drugs. The medication dissolves without ...

Pfizer introduces Rimegepant ODT in India for migraine treatment, offering rapid, sustained relief without overuse headache risk. New Delhi, Nov 17 (PTI) Drug maker Pfizer on Monday said it has ...